Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)

Phase 4 Completed 130 enrolled The University of Texas Health Science Center at San Antonio Takeda Pharmaceuticals North America, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.

Timeline

Start: 2006-06
Primary completion: 2011-12
Completion: 2011-12

Outcome

Met primary endpoint

registry analysis (superiority test); E to A Ratio After Pioglitazone Treatment; p <0.01; ANOVA NCT01588470 ↗

paper Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). PMID 28847910 ↗

Publications

Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes Care. 2017 Nov;40(11):1530-1536. doi: 10.2337/dc17-0078. Epub 2017 Aug 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	45 mg	—